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Purpose: To estimate the population effect size for resistance exercise training (RET) 
effects on anxiety and to determine whether variables of logical, theoretical, and/or 
prior empirical relation to anxiety moderate the overall effect. 
Methods: Thirty-one effects were derived from 16 articles published before February, 
2017, located using Google Scholar, MEDLINE, PsycINFO, PubMed, and Web of 
Science. Trials involved 922 participants and included both randomization to RET 
(n=486) or a non-active control condition (n=436), and a validated anxiety outcome 
measured at baseline, mid- and/or post-intervention. Hedges' d effect sizes were 
computed and random effects models were used for all analyses. Meta-regression 
quantified the extent to which participant and trial characteristics moderated the mean 
effect. 
Results: RET significantly reduced anxiety symptoms (Δ=0.31, 95%CI: 0.17-0.44; 
z=4.43; p<0.001). Significant heterogeneity was not indicated (QT(30)=40.5, p>0.09; 
I²=28.3%, 95%CI: 10.17%-42.81%); sampling error accounted for 77.7% of observed 
variance. Larger effects were found among healthy participants (Δ=0.50, 95%CI: 
0.22-0.78) compared to participants with an illness (Δ=0.19, 95%CI: 0.06-0.31, 
z=2.16, p<0.04). Effect sizes did not significantly vary according to sex (β=-0.31), 
age (β=-0.10), control condition (β=0.08), program length (β=0.07), session duration 
(β=0.08), frequency (β=-0.10), intensity (β=-0.18), anxiety recall time frame 
(β=0.21), or whether strength significantly improved (β=0.19) (all p≥0.06). 
Conclusions: RET significantly improves anxiety symptoms among both healthy 
participants and participants with a physical or mental illness. Improvements were not 
moderated by sex, or based on features of RET. Future trials should compare RET to 
other empirically-supported therapies for anxiety. 
Abstract 
 Inclusion criteria were: (1) English language peer-reviewed publications, (2) 
randomized allocation to either an exercise intervention or a non-active control 
condition, and (3) an anxiety outcome measured at baseline and at mid- and/or 
post-intervention.  
 Investigations were excluded that (1) included exercise as one part of a 
multicomponent intervention but did not include the additional component in a 
comparison condition, and/or (2) compared exercise only with an active treatment.  
Methods 
The available evidence supports the anxiolytic effects of acute exercise, and 
exercise training among otherwise healthy adults, adults with a chronic illness, and 
anxiety disorder patients. 
Although aerobic exercise training has well-established effects on anxiety that are 
comparable to other empirically-supported treatments, the anxiolytic effects of 
RET remain understudied. 
To date there has been no quantitative synthesis of the available empirical 
evidence, particularly randomized controlled trials. 
Background 
Hedges’ d effect sizes were calculated by subtracting the mean change in the comparison 
condition from the mean change in the exercise condition, and dividing this difference by 
the pooled standard deviation of baseline scores.  
Meta-regression was used as the overall analysis of moderator effects. Random effects 
models were used with macros (SPSS MeanES, MetaReg; SPSS, Inc) to aggregate mean 
effect size delta (Δ) and to test variation in effects according to moderator variables.   
Moderators were selected based on theoretical, practical, and/or prior empirical relation 
with anxiety and/or exercise effects on anxiety.  
Data Synthesis and Analysis 
Twenty-seven of 31 effects (87.1%) were larger than zero.  
The mean effect size Δ was 0.31 (95%CI: 0.17-0.44; z=4.43; p<0.001).  
 Significant heterogeneity was not indicated (QT(30)=40.5, p>0.09; I
2=28.3%, 95%CI: 
10.17%-42.81%), and sampling error accounted for 77.7% of observed variance.  
The fail-safe number of effects was 151 
Larger effects were derived from studies in which participants were healthy (Δ=0.50, 
95%CI: 0.22-0.78) compared to physically- or mentally-ill participants (Δ=0.19, 95%CI: 
0.06-0.31, z=2.16, p<0.04).  
Effect sizes did not significantly vary according to sex (β=-0.31), age (β=-0.10), control 
condition (β=0.08), program length (β=0.07), session duration (β=0.08), frequency (β=-
0.10), intensity (β=-0.18), supervision (β=0.06), primary outcome (β=0.29), recall (β=0.21), 
or a significant improvement in strength (β=0.19) (all p≥0.07). 
Effects were similar for the RET interventions (Δ=0.13, 95%CI: 0.03-0.29) and AET 
interventions (Δ=0.18, 95%CI: 0.03-0.33) .  
When directly comparing the effects of RET to AET, with RET serving as the intervention 
group and AET serving as the control group in Hedges’ d calculations, no significant 
differences were found (Δ=-0.07, 95%CI: -0.22 to 0.09). 
 
Results 
Clear and complete information regarding adherence, 
compliance, attendance, session duration, and intensity is 
needed. 
There is a critical lack of studies comparing RET and AET 
within the same study sample.  
Researchers should attempt to match RET with AET as best 
as possible on multiple relevant features of the exercise 
stimulus (e.g., intensity/load, time spent actively engaged in 
exercise, muscle groups exercised). 
The evidence regarding the effects of RET among 
individuals with an anxiety disorder and in those with 
subclinical levels of anxiety is limited. RCTs of RET effects 
on anxiety in those with subclinical or prodromal levels of 
anxiety are needed.  
Future Research 
The empirical evidence reviewed herein supports RET as a 
potential low-risk, alternative or adjuvant therapy for anxiety 
symptoms.  
 Future trials should compare RET to other empirically-
supported therapies for anxiety, examine plausible 
neurobiological mechanisms of the anxiolytic effects of 
RET, and more rigorously examine the optimal total 
resistance exercise dose required to improve anxiety. 
Conclusions 
Univariate Moderator Analysis 
Forest Plot of Unweighted Distribution of Hedges’ d 
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Records identified through the following databases: 
MEDLINE, Google Scholar, Web of Science, 
PubMed, SPORTDiscus, and PsycINFO (n = 1,659) 
Records remaining after 
duplicates removed (n = 1,117) 
 
 
Records excluded based on 
title and abstract (n = 626) 
Titles and abstracts screened for inclusion 
and exclusion criteria (n = 1,117) 
Full-text articles assessed 
for inclusion and exclusion 
criteria (n = 491) 
Full-text articles excluded (n =475) 
• Active control group (n = 68) 
• No anxiety outcome (n = 227) 
• Conference abstract (n = 51) 
• Acute bout (n = 11) 
• Not RET alone (n = 41) 
• Other (n = 77) 
Studies included in systematic  
review (n = 16) 
Abbreviations: POMS-T, Profile of Mood States – Tension; SCL-90, Hopkins Symptom Checklist; STAI-T, State-Trait Anxiety Inventory – Trait; STAI-S, State-Trait Anxiety Inventory – State; MHFI-A, Mental Health Functioning Index – Anxiety; HADS-A, Hospital 
Anxiety and Depression Scales – Anxiety; DASS-21, Depression, Anxiety, and Stress Scale – 21; BRUMS-T, Brunel Mood Scale – Tension; GAD, generalized anxiety disorder; COPD, chronic obstructive pulmonary disease; ES, effect size; CI, confidence intervals 
Participant & Trial Characteristics 
Study Measure Intensity Duration(wk) Participant characteristics Control Sex Age(y) Hedges’ d (ES ± 95%CI)  
Aidar et al. [25] STAI-S Moderate 12 Ischemic stroke Usual care Mixed 43-60 0.26 (-0.55 to 1.06) 
Aidar et al. [25] STAI-T Moderate 12 Ischemic stroke Usual care Mixed 43-60 0.24 (-0.57 to 1.04) 
Courneya et al. [30] STAI-S Moderate Mid-treatment Breast-cancer Usual care Female 25-78 0.16 (-0.15 to 0.46) 
Courneya et al. [30] STAI-S Moderate Post-treatment Breast-cancer Usual care Female 25-78 0.08 (-0.23 to 0.38) 
Damush et al. [33] MHFI-A Moderate 8 Elderly Wait list Female 62-74 0.29 (-0.21 to 0.79) 
Goldfield et al. [21] BRUMS-T Moderate 22 Obese adolescents No treatment Mixed 14-18 0.14 (-0.18 to 0.46) 
Herring et al. [26] POMS-T Moderate 2 GAD Wait list Female 18-37 0.62 (-0.28 to 1.51) 
Herring et al. [26] STAI-T Moderate 2 GAD Wait list Female 18-37 0.14 (-0.74 to 1.02) 
Herring et al. [26] POMS-T Moderate 4 GAD Wait list Female 18-37 0.15 (-0.72 to 1.03) 
Herring et al. [26] STAI-T Moderate 4 GAD Wait list Female 18-37 0.36 (-0.52 to 1.25) 
Herring et al. [26] POMS-T Moderate 6 GAD Wait list Female 18-37 1.05 (0.12 to 1.99) 
Herring et al. [26] STAI-T Moderate 6 GAD Wait list Female 18-37 0.52 (-0.37 to 1.41) 
Herring et al. [41] HADS-A Moderate 12 Morbidly obese Usual care Mixed 24-68 -0.49 (-1.47 to 0.49) 
Lau et al. [20] HADS-A Vigorous 6 Obese adolescents Usual care Mixed 10-17 0.41 (-0.25 to 1.07) 
Martins et al. [22] POMS-T Moderate 16 Elderly No treatment Mixed 65-95 -0.34 (-0.89 to 0.20) 
Norvell et al. [23] SCL-90 Moderate 16 Law enforcement personnel Wait list Male 25-40 1.17 (0.38 to 1.96) 
Nyberg et al. [32] HADS-A Moderate 8 COPD Other Mixed 61-74 0.34 (-0.26 to 0.09) 
O'Reilly et al. [39] HADS-A Low 36 People with knee pain No treatment Mixed 40-80 0.14 (-0.15 to 0.43) 
Rahmani-Nia et al. [39] STAI-S Moderate 8 Untrained college students No treatment Not reported 20-23 0.43 (-0.19 to 1.06) 
Rahmani-Nia et al. [39] STAI-T Moderate 8 Untrained college students No treatment Not reported 20-23 0.32 (-0.30 to 0.95) 
Tsutsumi et al. [28] STAI-T Moderate 12 Elderly No treatment Female 60-86 1.50 (0.59 to 2.40) 
Tsutsumi et al. [28] STAI-S Moderate 12 Elderly No treatment Female 60-86 0.87 (0.03 to 1.70) 
Tsutsumi et al. [28] POMS-T Moderate 12 Elderly No treatment Female 60-86 0.63 (-0.19 to 1.45) 
Tsutsumi et al. [28] STAI-T Vigorous 12 Elderly No treatment Female 60-86 0.89 (0.05 to 1.73) 
Tsutsumi et al. [28] STAI-S Vigorous 12 Elderly No treatment Female 60-86 0.64 (-0.18 to 1.46) 
Tsutsumi et al. [28] POMS-T Vigorous 12 Elderly No treatment Female 60-86 0.85 (0.01 to 1.68) 
Vizza et al. [31] DASS-21 Moderate 12 Polycystic ovarian syndrome Usual care Female 21-32 0.53 (-0.58 to 1.64) 
Vlachopoulou et al. [29] STAI-S Moderate 8 Chemically dependent No treatment Male 22-43 -0.75 (-1.76 to 0.26) 
Vlachopoulou et al. [29] STAI-T Moderate 8 Chemically dependent No treatment Male 22-43 0.82 (-0.20 to 1.83) 
Zanuso et al. [24] POMS-T Vigorous 12 Elderly Wait list Mixed 65-78 0.07 (-0.81 to 0.94) 
Zanuso et al. [24] STAI-T Vigorous 12 Elderly Wait list Mixed 65-78 -0.08 (-0.96 to 0.80) 
Effect moderator Contrast 
weights 
Effects (k) Δ 95% CI 
 
Contrast p-
value 
Sex 
Female  
Mixed  
Male 
 
-1 
0.5 
0.5 
 
16 
10 
5 
 
0.44 
0.11 
0.43 
 
0.24 to 0.63 
-0.06 to 0.27 
-0.11 to 0.96 
 
0.07 
Age(y) 
<25 
25-54 
55+ 
 
0.5 
0.5 
-1 
 
10 
8 
12 
 
0.31 
0.26 
0.40 
 
0.11 to 0.51 
-0.03 to 0.55 
0.13 to 0.66 
 
0.56 
Health 
Healthy  
Physical illness  
Mental illness 
 
1 
-0.5 
-0.5 
 
13 
10 
8 
 
0.50 
0.15 
0.37 
 
0.22 to 0.78 
0.02 to 0.29 
0.01 to 0.73 
 
0.03 
Control 
No treatment  
Usual care  
Wait list 
 
1 
-0.5 
-0.5 
 
13 
6 
10 
 
0.40 
0.12 
0.41 
 
0.13 to 0.66 
-0.08 to 0.32 
0.16 to 0.67 
 
0.62 
Program 
<12 weeks  
12+ weeks 
 
-1 
1 
 
14 
15 
 
0.28 
0.42 
 
0.18 to 0.50 
0.15 to 0.70 
 
0.68 
Session 
<60min  
60+ min 
 
-1 
1 
 
22 
7 
 
0.29 
0.33 
 
0.15 to 0.42 
-0.08 to 0.74 
 
0.63 
Frequency 
2d/week 
3d/week 
 
-1 
1 
 
8 
21 
 
0.41 
0.34 
 
0.13 to 0.70 
0.17 to 0.54 
 
0.56 
Intensity 
Moderate 
Vigorous 
 
1 
-1 
 
24 
6 
 
0.31 
0.47 
 
0.14 to 0.47 
 0.14 to 0.80 
 
0.27 
Supervised 
Combination 
Yes 
 
-1 
1 
 
5 
20 
 
0.10 
0.20 
 
-0.44 to 0.65 
0.08 to 0.32 
 
0.77 
Primary Outcome 
Anxiety 
No 
Yes 
 
 
-1 
1 
 
 
8 
23 
 
 
0.16 
0.42 
 
 
0.01 to 0.31 
0.22 to 0.61 
 
 
0.07 
State vs. Trait 
State 
Trait 
 
-1 
1 
 
22 
9 
 
0.27 
0.42 
 
0.12 to 0.43 
0.16 to 0.69 
 
0.17 
Significant 
Improvement in 
Strength 
Yes 
No 
Not reported 
 
 
 
1 
-0.5 
-0.5 
 
 
 
21 
2 
8 
 
 
 
0.37 
0.18 
0.20 
 
 
 
0.20 to 0.54 
-0.07 to 0.43 
-0.17 to 0.56 
 
 
 
0.24 
 
